Malaria Research

Malaria is a disease caused by mosquito-borne parasites that infect 350-500 million and kill over one million people each year. Chloroquine and its derivatives have been used to successfully treat Malaria in the past, but many parasites, such as Plasmodium Vivax, have grown increasingly resistant to these drugs. This has led to a resurgence of Malaria in the past 10 years. Therefore, development of vaccines and other preventatives has become a priority for malaria research, with many efforts focused on targeted disruption of the asexual reproduction phase of the parasite's life cycle. However, P. vivax preferentially infects and reproduces within reticulocytes, immature red blood cells that constitute only a small fraction of circulating blood. Vaccine research and development has been hindered by the difficulty in isolating a pure volume of these cells.

Arteriocyte is developing unique rapid reticulocyte production technology to address this problem. The technology produces large yields of 80% pure duffy-antigen positive Reticulocytes from a small volume of hematopoietic stem cells. This will provide a unique platform to jump start research of P. vivax malaria and stimulate rapid development of effective vaccines. Arteriocyte's innovative tools for malaria research will lead to significant improvement in infection prevention for populations living or operating in tropical regions worldwide.